{"id":"https://openalex.org/W7199447659","doi":null,"title":"Glucagon-like peptide-1 receptor agonists: practical use in type 2 diabetes","display_name":"Glucagon-like peptide-1 receptor agonists: practical use in type 2 diabetes","alternate_titles":[],"publication_year":2022,"publication_date":"2022-03-21","ids":{"openalex":"https://openalex.org/W7199447659"},"language":"en","primary_location":{"id":"pmh:oai:jupiter.its.unimelb.edu.au:11343/299795","doi":null,"is_oa":false,"landing_page_url":"https://hdl.handle.net/11343/299795","pdf_url":null,"source":{"id":"https://openalex.org/S4377196259","display_name":"Minerva Access (University of Melbourne)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I165779595","host_organization_name":"The University of Melbourne","host_organization_lineage":["https://openalex.org/I165779595"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":null,"raw_type":"Journal Article"},"parent_works":[],"lineage":["https://openalex.org/W7199447659"],"child_works_count":0,"type":"article","is_traditional":true,"indexed_in":[],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5048148363","display_name":"Y-A Park","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Park, Y-A","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5001758021","display_name":"Christopher James Yates","orcid":"https://orcid.org/0000-0003-4559-4482","observed_orcids":["https://orcid.org/0000-0003-4559-4482"]},"institutions":[],"countries":[],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Yates, C","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5145097520","display_name":"R Barmanray","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Barmanray, R","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":0.0,"has_fulltext":false,"cited_by_count":0,"reviewed_by_count":0,"citation_normalized_percentile":{"value":0.0,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":null,"issue":null,"first_page":null,"last_page":null},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10401","display_name":"Diabetes Treatment and Management","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10401","display_name":"Diabetes Treatment and Management","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10560","display_name":"Diabetes Management and Research","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12539","display_name":"Pharmacology and Obesity Treatment","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2736","display_name":"Pharmacology (medical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/glp-1-receptor-agonists","display_name":"GLP-1 receptor agonists","score":0.9950000047683716},{"id":"https://openalex.org/keywords/type-2-diabetes","display_name":"type 2 diabetes","score":0.9980000257492065},{"id":"https://openalex.org/keywords/patient-counseling","display_name":"patient counseling","score":0.5860000252723694},{"id":"https://openalex.org/keywords/injection-technique","display_name":"injection technique","score":0.6470000147819519},{"id":"https://openalex.org/keywords/nausea","display_name":"nausea","score":0.7319999933242798},{"id":"https://openalex.org/keywords/adverse-events","display_name":"adverse events","score":0.9139999747276306},{"id":"https://openalex.org/keywords/glycemic-control","display_name":"glycemic control","score":0.8960000276565552},{"id":"https://openalex.org/keywords/cardiovascular-outcomes","display_name":"cardiovascular outcomes","score":0.8029999732971191},{"id":"https://openalex.org/keywords/renal-outcomes","display_name":"renal outcomes","score":0.8870000243186951},{"id":"https://openalex.org/keywords/weight-loss","display_name":"weight loss","score":0.9890000224113464},{"id":"https://openalex.org/keywords/primary-care-prescribing","display_name":"primary care prescribing","score":0.6179999709129333},{"id":"https://openalex.org/keywords/patient-selection","display_name":"patient selection","score":0.6169999837875366}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8198999762535095},{"id":"https://openalex.org/C2777180221","wikidata":"https://www.wikidata.org/wiki/Q3025883","display_name":"Type 2 diabetes","level":3,"score":0.7773000001907349},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.5902000069618225},{"id":"https://openalex.org/C177713679","wikidata":"https://www.wikidata.org/wiki/Q679690","display_name":"Intensive care medicine","level":1,"score":0.4724000096321106},{"id":"https://openalex.org/C170493617","wikidata":"https://www.wikidata.org/wiki/Q208467","display_name":"Receptor","level":2,"score":0.3668999969959259},{"id":"https://openalex.org/C555293320","wikidata":"https://www.wikidata.org/wiki/Q12206","display_name":"Diabetes mellitus","level":2,"score":0.35679998993873596},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.33570000529289246},{"id":"https://openalex.org/C2778938600","wikidata":"https://www.wikidata.org/wiki/Q389934","display_name":"Agonist","level":3,"score":0.3321000039577484},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.29440000653266907},{"id":"https://openalex.org/C544821477","wikidata":"https://www.wikidata.org/wiki/Q718113","display_name":"Weight loss","level":3,"score":0.2888000011444092},{"id":"https://openalex.org/C3018376624","wikidata":"https://www.wikidata.org/wiki/Q1100933","display_name":"Diabetes treatment","level":4,"score":0.28209999203681946},{"id":"https://openalex.org/C2779134260","wikidata":"https://www.wikidata.org/wiki/Q12136","display_name":"Disease","level":2,"score":0.2782999873161316},{"id":"https://openalex.org/C60644358","wikidata":"https://www.wikidata.org/wiki/Q128570","display_name":"Bioinformatics","level":1,"score":0.27300000190734863}],"mesh":[],"locations_count":1,"locations":[{"id":"pmh:oai:jupiter.its.unimelb.edu.au:11343/299795","doi":null,"is_oa":false,"landing_page_url":"https://hdl.handle.net/11343/299795","pdf_url":null,"source":{"id":"https://openalex.org/S4377196259","display_name":"Minerva Access (University of Melbourne)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I165779595","host_organization_name":"The University of Melbourne","host_organization_lineage":["https://openalex.org/I165779595"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":null,"raw_type":"Journal Article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","score":1.0,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W3183844899","https://openalex.org/W4283769318","https://openalex.org/W4413486746","https://openalex.org/W1863540633","https://openalex.org/W2952094692","https://openalex.org/W4313260808","https://openalex.org/W6920336404","https://openalex.org/W4394759794","https://openalex.org/W2902989158","https://openalex.org/W2519670213"],"abstract_inverted_index":{"Glucagon-like":[0],"peptide-1":[1],"receptor":[2],"agonists":[3],"(GLP-1RAs)":[4],"are":[5],"being":[6],"increasingly":[7],"prescribed":[8],"for":[9],"people":[10],"with":[11],"type":[12],"2":[13],"diabetes.":[14],"They":[15],"have":[16],"been":[17],"practice-changing":[18],"owing":[19],"to":[20,38,55,66,76],"their":[21],"glycaemic,":[22],"cardiovascular,":[23],"renal":[24],"and":[25,29,45,57,69,80],"weight":[26],"loss":[27],"benefits,":[28],"decreases":[30],"in":[31],"all-cause":[32],"mortality.":[33],"However,":[34],"counselling":[35,68],"is":[36],"crucial":[37],"advise":[39],"patients":[40,72],"of":[41,59],"safe":[42],"injection":[43],"techniques":[44],"common":[46],"adverse":[47],"events":[48],"such":[49],"as":[50],"nausea,":[51],"which":[52],"may":[53],"lead":[54],"cessation":[56],"avoidance":[58],"this":[60],"therapeutic":[61],"class.":[62],"A":[63],"four-phase":[64],"approach":[65],"selecting,":[67],"following":[70],"up":[71],"can":[73],"help":[74],"GPs":[75],"prescribe":[77],"GLP-1RAs":[78],"safely":[79],"effectively.":[81]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W7199447659","counts_by_year":[],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2026-08-07T00:00:00"}
